Clinical features and prognostic factors of surgical resected pulmonary neuroendocrine carcinoma
Objective: To investigate the characteristics of surgical resected pulmonary neuroendocrine carcinoma and to analyze the prognostic factors. Methods: We retrospectively reviewed the clinical data and genetic state of 65 patients with pulmonary neuroendocrine carcinoma, and the survival rate was calculated by Kaplan-Meier method and log-rank test was used to compare the survival rates. Univariate and multivariate factors for survival were analyzed by COX proportional hazards regression model. Results: There was no significant difference in clinical characteristics of 65 cases of pulmonary neuroendocrine carcinoma (P>0.05); the genetic change was given priority to with PIK3CA gene mutations, the difference in the median overall survival time among small-cell cancer (26.7 months), large cell neuroendocrine carcinoma (30.4 months) and carcinoid (did not reach) was not significant (P=0.039); and the difference in the gene subtype staging was statistically significant by the single factor analysis in small-cell cancer (P<0.05). Conclusion: Pulmonary neuroendocrine carcinoma genetic change is rare, and it is given priority to with PIK3CA gene mutations, common genomic aberrations are rare for pulmonary neuroendocrine carcinoma. Molecular profiles vary widely among different subtypes of pulmonary neuroendocrine carcinoma. Carcinoid offers better survival than pulmonary large-cell neuroendocrine carcinoma and small cell lung cancer, whereas no survival difference existed between pulmonary large-cell neuroendocrine carcinoma and small cell lung cancer.